Alnylam Execs Foresee Partnerships in 2010, Provide Few Details as Pipeline Advances | GenomeWeb

By Doug Macron

Alnylam Pharmaceuticals expects to forge new collaborations over 2010, but company officials last week declined to provide specific guidance on its partnering objectives after falling short of previous expectations.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Tech companies like Microsoft are looking into DNA as a data storage device, Scientific American writes.

The New York Times writes that the Max Planck Institute for Infection Biology's Emmanuelle Charpentier has always been on the move, though now it's more about CRISPR.

The European Union calls for all publicly funded scientific papers to be immediately freely accessible to the public by 2020.

In PNAS this week: peanut subgenome progenitor sequence, homozygosity mapping and linkage analyses using exome data, and more.